A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors. Meeting Abstract

International Collaboration

cited authors

  • Sonpavde, Guru P.; Call, Justin A.; Falchook, Gerald Steven; Garmezy, Benjamin; Rasco, Drew W.; Liu, Lan; Niu, Tiantian; He, Jenna; Zhang, Congcong; Kochan, Jarema; Rebello, Sam; Russo, Giuseppe; Chen, Viola; Krishnan, Suba

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16